Ups and downs: The PPARγ/p-PPARγ seesaw of follistatin-like 1 and integrin receptor signaling in adipogenesis

Dongliang Fang1,3, Xinyi Shi1,3, Xiaowei Jia1, Chun Yang1, Lulu Wang1, Baopu Du1, Tao Lu1, Lin Shan2, Yan Gao1,*

ABSTRACT

Objective: Although Follistatin-like protein 1 (FSTL1), as an “adipokine”, is highly expressed in preadipocytes, the detail role of FSTL1 in adipogenesis and obesity remains not fully understood.

Methods: In vitro differentiation of both Fstl1−/− murine embryonic fibroblasts (MEFs) and stromal vascular fraction (SVF) were measured to assess the specific role of FSTL1 in adipose differentiation. Fstl1 adipocyte-specific knockout mice were generated to evaluate its role in obesity development. Gene expression analysis and phosphorylation patterns were performed to check out the molecular mechanism of the biological function of FSTL1.

Results: FSTL1 deficiency inhibited preadipocytes differentiation in vitro and obesity development in vivo. Glycosylation at N142 site was pivotal for the biological effect of FSTL1 during adipogenesis; the conversion between PPARγ and P-PPARγ was the key factor for the function of FSTL1. Molecular mechanism studies showed that FSTL1 functions through the integrin/FAK/ERK signaling pathway.

Conclusions: Our results suggest that FSTL1 promotes adipogenesis by inhibiting the conversion of PPARγ to p-PPARγ through the integrin/FAK/ERK signaling pathway. Glycosylated modification at N142 of FSTL1 is the key site to exert its biological effect.

© 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords Obesity; Adipogenesis; FSTL1; Integrin/FAK/ERK; PPARγ/p-PPARγ

1. INTRODUCTION

Obesity has been recognized as one of the most serious public health problems, which is caused by the accumulation of white fat as a result of excessive energy intake. White adipose tissue (WAT) is the main “storage site” of excess energy, primarily in the form of triglycerides [1]. It has been reported that an increased adipocyte number (hyperplasia) and/or size (hypertrophy) contributes to development of obesity [2–4]. Study on exploring the mechanism of adipogenesis has great theoretical value and clinical significance for explaining the pathogenesis of obesity and combating obesity.

Adipogenesis is the process of mesenchymal stem cells (MSCs) undergo commitment to become preadipocytes and the program by which preadipocytes differentiate into adipocytes [5]. Members of the BMP and Wnt families are key mediators of stem cell commitment to produce preadipocytes [6,7]. During the maturing process, phosphorylation of the transcription factor CCATT enhancer binding protein β (C/EBPβ) triggers transcription of peroxisome proliferator–activated receptor–γ (PPARγ) and C/EBPα, which coordinately activate genes whose expression produces the adipocyte phenotype [8,9]. Among all transcription factors known to promote adipocyte development, none are as critical as PPARγ, which is considered the principal regulator of adipogenesis [10–12]. Phosphorylation of PPARγ was proved to inhibit PPARγ activity and that PPARγ-binding compounds that modulate serine phosphorylation within the PPARγ ligand-binding domain can be further developed as potential anti-obesity drugs [13,14]. Follistatin-like protein 1 (FSTL1), also known as Transforming growth factor-beta 1 (TGFβ)-induced clone 36 (TSC-36), is highly expressed during embryonic development, loss of FSTL1 can inhibit the development of respiratory system and tracheal chondrogenesis in fetal mice [15–17]. FSTL1 can also regulate the formation and differentiation of mesenchymal stem cells into cartilage, which is closely related to the occurrence and development of arthritis [18,19]. FSTL1 was found to express highly in adipose tissue and was considered as an “adipokine” [20,21]. During the differentiation of pre-adipocytes into adipocytes, Fstl1 showed a transient short high-level expression to become subsequently downregulated to the background level [22]. This suggests that FSTL1 may play a role in adipogenesis and obesity. Glycosylated modification is a determinant of biological activity in cardiomyocytes, the glycosylated form promoting proliferation and the
non-glycosylated working anti-apoptotic [23]. The glycosylation state shows differences between species and tissues, which might underline the differences observed in *in vitro* studies. In the sequence of mouse FSTL1, three potential sites for N-glycosylation and two for O-glycosylation are present, and *in vitro* studies have shown that only the three asparagine residues Asp<sup>195</sup>, Asp<sup>175</sup>, and Asp<sup>178</sup> are N-glycosylated [17]. A single N-Glycosylation site (N180) in human FSTL1 was shown to be sufficient to increase cardiomyocytes proliferation and cardiac regeneration [24].

Previous reports have shown that integrin-β1 regulates various biological functions, including cell migration and signal transduction, particularly in the context of cancer [25]. The activity of integrin-β1 is proposed to be impaired during adipogenesis. Adipocyte differentiation is regulated by the downstream signaling of integrin-β1 such as FAK and ERK [26,27]. FSTL1 was proposed as not only an antagonist of BMP4 but also an agonist of TGF-β signaling, which plays important roles during lung fibrosis. Deficiency of FSTL1 leads to reduced collagen accumulation, which is a key factor in lung injury [15,28]. Building on these reports, we proposed the hypothesis that FSTL1 may regulate adipogenesis through the integrin-β1/FAK signaling pathway. In our previous study, we have shown that glycosylated FSTL1 secreted by brown adipocytes promotes the thermogenic program in BAT [29]; however, the expression pattern of FSTL1 is quite different in WAT and BAT. We planned to explore the role of FSTL1 in white fat, based on the current popular view that different shades of adipose tissue should be considered as different organs [30]. In this context, it is demonstrated that FSTL1 facilitates adipogenesis by inhibiting PPARY phosphorylation which is regulated by the integrin-β1/FAK/ERK signaling pathway.

2. MATERIALS AND METHODS

2.1. Animal studies

*Fstl1*<sup>lox/lox</sup> mice of a mixed background (129Sv/C57BL/6J) were generated by Model Animal Research Center of Nanjing University; the details were shown in our previously study. *Fstl1*<sup>lox/lox</sup> mice were bred with *EIIa-Cre* and *p2F(Fabp4)-Cre* mice to generate *Fstl1*<sup>+/−</sup> mice and *Fstl1*<sup>ad KO</sup> mice. The primer set of *Fstl1* is: forward, 5′-TCCAC CTTCCGCTTCAACT-3′; reverse, 5′-GAACCTGCGCTGCTGTGC-3′. The primer set of *ap2-Cre* is: forward, 5′-ACCGCAGCTATCAAATCG-3′; reverse, 5′-TATACGGTGCAGGAC-3′. All animal experiments were performed in accordance with the Administration Regulations on Laboratory Animals of Beijing Municipality. All animals were maintained under 12 h/12 h light/dark cycle under constant conditions of room temperature (22 ± 1°C) and humidity with free access to food and water. For HDF feeding experiments, 6–8 weeks old male mice were fed with HDF (60 kcal%, Research Diets Inc. D12492) diets for up to 14 weeks. Mouse genotyping was performed using genomic DNA isolated from mouse tails.

2.2. Glucose tolerance test and insulin tolerance test

To determine glucose tolerance, 16-h-fasted mice were intraperitoneally administered with glucose (1 g/kg of body weight). To determine insulin sensitivity, 6-h-fasted mice were intraperitoneally administered with insulin (1 U/kg of body weight). Blood glucose level from tail vein blood was quantified with glucose meter or was measured using DMEM/F12 Glutamax I, containing 10% fetal bovine serum (FBS) supplemented with 5 mg/mL insulin, 0.25 mM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), and 10 mM rosiglitazone for 2 days, after which the dexamethasone and IBMX were removed, and the cells were allowed to undergo full adipogenic differentiation.

For 3T3-L1 and SVF adipogenic differentiation, cells of 100% confluence were kept in growth medium for 2 days and induced with induction medium for 2 days, differentiation medium (without T3) for the following 6 days.

For PPARY activation or P-ERK1/2 inhibition, rosiglitazone (5 μM) or U0126 (10 μM) was incubated with indicated durations as shown in figures. For dish coating, diluted Collagen Type I with 5 μg/cm<sup>2</sup> was performed according to the instructions (Santa Cruz, sc-136157). Recombinant mouse FSTL1 protein was incubated with cells for 24 h (1738-FN, R&D Systems, 100 ng/mL).

2.4. Morphological study

For adipocytes Oil red O staining, cultured cells were washed with PBS and fixed with 10% formaldehyde for 15 min at room temperature. The cells were then stained using the Oil red O working solutions (5 g/L in isopropanol) and 4 ml ddH<sub>2</sub>O for 30 min. After staining, the cells were washed with 60% isopropanol and pictured. For adipose tissues, frozen sections were subjected with Oil red O solutions. The isolated adipose tissues were fixed in 4% formaldehyde/PBS and maintained at 4 °C until use. The fixed tissues were dehydrated and processed for paraffin embedding, and 4-mm sections were cut, followed by staining with hematoxylin-eosin.

2.5. RNA-sequencing, RNA interference and lentivirus production

To knock down FSTL1 in 3T3-L1 cells, lentiviral vector (hU6-MCS-Ubiquitin-EGFP-ires-puromycin) containing the short-hairpin RNA (shRNA) specifically targeting FSTL1 or a negative control sequence was constructed (GeneChem, Shanghai, China). The sequences were as follows:

| Fstl1-RNAi (55013-1) | NM_008047 5′-AGATGAAAGAGCCTATGATAC-3′ |
|--------------------|------------------------------------------|
| Fstl1-RNAi (55014-1) | NM_008047 5′-AGCTGAAACCAAAGAGAT-3′ |
| Fstl1-RNAi (55015-1) | NM_008047 5′-CTGCATTGAGCAATGCAA-3′ |

Primers for the glycosylation site mutation of N142, N173 and N178 were designed with Oligo7.0, asparagine (N) was mutated to glutamine (Q), lentivirus were constructed by GeneChem corporation. The infection of virus was performed according to the manufacturer’s instructions. To overexpress FSTL1 in 3T3-L1 cells, GV141 vector (CMV-MCS-3FLAG-SV40-Neomycin) containing a FSTL1 coding sequence (NM_008047) was constructed (GeneChem, Shanghai, China). 3T3-L1 cells were incubated with 2 μg RNA and 6 μL Lipofectamine 3000 diluted in Opti-MEM for 48 h and then subjected to differentiation. 3T3-L1 cells with Fstl1 knockdown and control group were induced for differentiation with induction medium. After 2 days, total RNA was isolated using Trizol. RNA-sequencing and data sorting were performed by CapitalBio Technology.

2.6. Protein extraction and western blotting

Cells were lysed in the RIPA buffer with protease inhibitor and protein phosphatase inhibitor. Protein concentration was determined with BCA

Original Article
The reaction protocol for protein deglycosylation was followed according to the manufacturer’s recommendation. For GST pull-down assays, about 5 mg of the concentrated GST fusion proteins with 30 ml of glutathione-Sepharose beads was incubated with 5–8 ml of in vitro transcribed/translated products in binding buffer (75 mM NaCl, 50 mM Hepes, pH 7.9) at 4 °C for 2 h in the presence of the protease inhibitor mixture. The beads were washed 5 times with binding buffer, resuspended in 30 ml of 2× SDS-PAGE loading buffer, and detected by western blotting.

2.8. Real-time quantitative PCR analysis

Cellular mRNA was isolated using total RNA kit (DP419, TIANGEN). The concentration was measured with NanoDrop2000, cDNA synthesis was performed with SuperReal PreMix Plus (SYBR Green) Kit (FP205, TIANGEN). All the primer sequences are shown in Supporting Table 1.

2.9 Reaction for protein deglycosylation

The reaction protocol for protein deglycosylation was followed according to the instructions of protein deglycosylation mix II kit (P6044; NEB). A total of 100 μg of glycoprotein was dissolved in 40 μl H2O. To the native glycoprotein, 5 μl 10x deglycosylation and mix buffer 1 were added. Next, 5 μl protein deglycosylation mix II was added, and the solution was mixed gently. The reaction mixture was incubated at 25 °C (room temperature) for 30 min. The reaction mixture was further incubated at 37 °C for 16 h. Proteins were immunoblotted using FSTL1 antibody to confirm the deglycosylation was effective. Brown adipocytes were incubated with supernatant, deglycosylation supernatant, or Deglycosylation Mix for 12 h.

Protein samples (Thermo Scientific, Rockford, IL, USA), the amount of protein sample loading was 40–60 μg per lane. The primary antibodies were as follows: FSTL1 (1:2000, AF1738 R&D Systems), PPARγ (1:1000, #2443 Cell Signaling Technology), p-PPARγ (phospho-Ser112) (1:1000, LS-C416660 LifeSpan BioSciences), ERK1/2 (1:1000, #4695 Cell Signaling Technology), p-ERK1/2 (phospho-Thr202/Tyr204) (1:1000, #4370 Cell Signaling Technology), p-FAK (phospho Y397) (1:1000, ab81298), FAK (1:1000, #3284 Cell Signaling Technology), GAPDH (1:3000, #5174 Cell Signaling Technology).

2.10. Statistical analysis

All statistical analyses were performed using GraphPad Prism (v.5.0). Statistical significance was defined as *p < 0.05, **p < 0.01, and ***p < 0.005, and determined by two-tailed Student’s t tests (for comparison of two experimental conditions) or ANOVA (for comparison of three or more experimental conditions). Data are representative of at least three independent experiments.

3. RESULTS

3.1. FSTL1 was identified as a potential adipogenic cytokine

To study the role of FSTL1 in adipogenic differentiation, the protein and mRNA levels of Fstl1 in different parts of adipose tissue of C57BL/6J mice were measured. FSTL1 protein was highly expressed and glycosylated in brown adipose tissue (BAT), and both glycosylated and non-glycosylated protein were detected in WAT, including inguinal white adipose tissue (iWAT), epididymal white adipose tissue (eWAT), and retroperitoneal white adipose tissue (rWAT) (Figure 1A). The mRNA level of Fstl1 was higher in iWAT, but lower in BAT (Figure 1B). To further determine the effect of FSTL1 in white adipocyte formation, mouse embryonic fibroblast (MEFs), stromal vascular fraction (SVF), and 3T3L1 were induced for differentiation. As the whole-body ablation Fstl1 homozygous mice died at birth, we obtained MEFs from Fstl1−/−/KO embryos to study its function when FSTL1 is completely lost. Fstl1 protein and mRNA levels were initially upregulated after induction and then gradually reduced to basal level (Figure 1C–F). These results suggest that FSTL1 may play a role in adipocyte precursors differentiation.

3.2. FSTL1 promoted adipogenesis by inhibiting the conversion of PPARγ to p-PPARγ

Adipocyte formation is a process enclosing six specific orchestrated steps but is broadly divided into two phases. The first phase is the differentiation of mesenchymal precursors, which can differentiate into preadipocytes, while the second phase consists of the differentiation of preadipocytes into mature adipocytes [31]. As the whole-body ablation Fstl1 homozygous mice died at birth, we obtained MEFs from Fstl1−/−/KO embryos to study the detail role of FSTL1 in whole period of adipogenic differentiation. The genotypes (Fstl1−/−/WT, Fstl1−/−/KO) were verified, and no FSTL1 protein was detected in KO MEFs (Figure s1A, B). The proliferation of MEFs, SVF was almost equal between WT and KO group (Figure s1C, D). MEFs and SVF were then induced for differentiation into adipocytes. Oil Red O staining for lipids revealed that there was almost no lipid accumulation in KO MEFs compared to WT group (Figure 2A, D). Histomorphological observation of mouse embryo sections by HE and Oil red O staining showed that the development of KO embryo adipose tissue was defective, and just a little bit of lipid accumulation was shown (Figure s1F, G). During adipogenic differentiation, the PPARγ/p-PPARγ ratio was significantly lower in the KO group than in the control group on the 4th and 6th days (Figure 2B, E). The expression of adipogenic genes (Fabp4, C/ebpα, Adiponectin) was much lower in KO cells, while Pparγ gene expression was almost equal (Figure 2C, F).

We carried out a series of knockdown and overexpression experiments with 3T3L1 cell line to check the role of FSTL1 in the adipogenic process. Knockdown and overexpression of FSTL1 in 3T3L1 were verified by Western blot and RT-PCR (Figure s2A–D). The proliferation of 3T3L1 was not altered by Fstl1 knockdown (Figure s1E). Consistent with the results of previous study, Fstl1 deficiency inhibited lipid accumulation and reduced the PPARγ/p-PPARγ ratio and adipogenic genes expression (Figure 3A–C). On the contrary, Fstl1 overexpression promoted lipid accumulation, PPARγ/p-PPARγ ratio, and adipogenic genes expression (Figure 3D–F). Consistent with previous study, Pparγ gene expression was not altered by Fstl1 reconstruction (Figure 3G–I).
Figure 1: The expression of FSTL1 in preadipocytes differentiation and adipose tissues of mice. (A) The protein levels of FSTL1 in inguinal white adipose tissue (iWAT), epididymal white adipose tissue (eWAT), retroperitoneal white adipose tissue (rWAT) and brown adipose tissue (BAT) of C57BL/6J mice. 50 kDa, glycosylated; 37 kDa, hypoglycosylated. (B) mRNA levels of Fstl1 in iWAT, eWAT, rWAT, and BAT were detected by RT-PCR. (C) Time course of FSTL1 protein levels during MEFs differentiation detected by western blot. (D) Time course of Fstl1, Pparγ, and C/ebpα gene expression during MEF differentiation by RT-PCR. (E, F) Time course of FSTL1 protein levels during SVF and 3T3L1 differentiation.

Figure 2: Fstl1 deletion inhibited the differentiation of MEFs and SVF by promoting PPARγ phosphorylation. (A) MEFs extracted from E13.5 wild-type (WT) and Fstl1−/− (KO) mouse embryos were induced to differentiate into adipocytes for 10 days and stained with Oil Red O. The oil red O stain was extracted and quantitated by measuring absorbance at 492 nm (n = 3). Scale bar, 200 μm 100 μm, 50 μm. (B) Western blot analysis of protein levels of PPARγ and p-PPARγ during MEF differentiation. PPARγ and p-PPARγ band intensities were normalized relative to the GAPDH bands, and the PPARγ/p-PPARγ ratio was calculated and analyzed. (C) Relative mRNA levels of adipogenic genes (Pparγ, Fabp4, C/ebpα, Adipoq) of MEFs (as in A) detected by qPCR. Two-way ANOVA followed by Bonferroni post-tests, n = 3. (D) SVF extracted from iWAT of E18.5 wild-type (WT) and Fstl1−/− (KO) mouse embryos were induced to differentiate into adipocytes and stained with Oil Red O. The oil red O stain was extracted and quantitated by measuring absorbance at 492 nm (n = 3). Scale bar, 200 μm 100 μm, 50 μm. (E) Western blot analysis of protein levels of PPARγ and p-PPARγ during SVF differentiation. PPARγ and p-PPARγ band intensities were normalized relative to the GAPDH bands, and the PPARγ/p-PPARγ ratio was calculated and analyzed. (F) Relative mRNA levels of adipogenic genes (Pparγ, Fabp4, C/ebpα, Adipoq) of SVF (as in D) detected by qPCR. Two-way ANOVA followed by Bonferroni post-tests, n = 3. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.005.
s2E, F). Taken together, these loss-of-function and gain-of-function data demonstrate that FSTL1 is essential for inducing the differentiation of adipocytes by inhibiting the conversion of PPARγ to p-PPARγ.

3.3. The biological activity of FSTL1 relied on N-glycosylated modification

It was reported that glycosylated or non-glycosylated FSTL1 showed different biological functions, suggesting that glycosylated modification is crucial for the FSTL1 protein [24]. To explore the role of glycosylation on the function of FSTL1 in the process of adipogenesis, we firstly isolated protein from 3T3L1 cells and supernatant. Western blot analysis showed that the molecular weight of FSTL1 in cells is 37kD, while the molecular weight of FSTL1 in supernatant is 50kD. When the medium was incubated with deglycosylation enzymes, the glycosylation on FSTL1 could be fully removed by the enzyme mix (Figure 4A). N-Glycosylation sites of FSTL1 were predicted by NetNGlyc 1.0 Server, while the molecular weight of FSTL1 in supernatant is 50kD. When the medium was incubated with deglycosylation enzymes, the glycosylation on FSTL1 could be fully removed by the enzyme mix (Figure 4A). N-Glycosylation sites of FSTL1 were predicted by NetNGlyc 1.0 Server, and three sites, including N142, N173, N178, were verified. We constructed three mutants (N142Q, N173Q, N178Q) and transfected into 3T3L1 cells for adipogenic differentiation. The protein expression of FSTL1 was mostly unaltered, while the molecular weight of FSTL1 extracted from media of triple-mutant cells was obviously smaller than that of control (Figure 4B). When all the three sites were mutated totally, there was almost no lipid accumulation. A single site mutation of N178 resulted moderate decrease of lipid accumulation, and it is much less if N173 site was mutated, while N142 mutation resulted almost no lipid accumulation compared to WT control (Figure 4C). N142 mutation decreased adipogenic genes expression, and the PPARγ/p-PPARγ ratio compared to WT control (Figure 4D,E). These results suggest that N-glycosylation is necessary for the function of FSTL1 in adipogenesis, the mutation of a single site (N142Q) is sufficient.

3.4. FSTL1 attenuated the conversion of PPARγ to p-PPARγ by reducing ERK1/2 phosphorylation

It has been reported that the phosphorylation of PPARγ could be modified by p-ERK1/2 [32]. We tried to find out whether the effect of FSTL1 was also related to the phosphorylation of ERK1/2. The effectiveness of p-ERK1/2 inhibitor (U0126) was firstly confirmed at concentration of 10 μM (Figure 5A). Oil-red O staining showed that Fstl1 knockdown inhibited lipid accumulation of 3T3L1 cells as shown in previous studies, while it was rescued by p-ERK1/2 inhibition with U0126 (Figure 5B). Meanwhile, the down-regulated mRNA levels of adipogenic genes (Fabp4, C/ebpα, Adiponectin) and lipogenic genes (Acc, Fas) resulted by Fstl1 knockdown recovered by U0126 (Figure 5C). The conversion of PPARγ to p-PPARγ was also rescued by p-ERK1/2 inhibition (Figure 5D).

To further verify the molecular axis of FSTL1 by inhibiting ERK1/2 phosphorylation and downstream PPARγ phosphorylation. We attempted to investigate the effect of activated PPARγ on ERK phosphorylation; the effectiveness of PPARγ agonist rosiglitazone (RG) was confirmed at concentration of 5 μM, and p-ERK1/2 level was not altered by RG (Figure 6A). The inhibition of lipid droplet aggregation and expression of mRNA levels of adipogenic genes (Fabp4, C/ebpα, Adiponectin) and lipogenic genes (Acc, Fas) resulted by Fstl1 knockdown was rescued by RG (Figure 6B,C). The conversion of PPARγ to p-PPARγ was also rescued by PPARγ agonist, while the protein level of...
Figure 4: A single site mutation of N142 glycosylation was sufficient for the function of FSTL1. (A) Western blot analysis of FSTL1 protein extracted from 3T3L1 cells and supernatant (upper panel). Western blot analysis of FSTL1 protein extracted from supernatant or supernatant reacted with deglycosylation enzymes. (B) Western blot analysis of FSTL1 protein both in cell lysate and media of 3T3L1 with N-glycosylation mutants (N142, N173, N178). (C) Glycosylated modification sites (N142, N173, N178) were mutated separately or totally in 3T3L1 fibroblasts. Oil Red O staining was measured after inducing differentiation for 8 days. The oil red O stain was extracted and quantitated by measuring absorbance at 492 nm, n = 3. Scale bar, 100 μm. (D) mRNA levels of adipogenic genes (Fabp4, C/ebpα, Adipoq) of 3T3L1 cells with N142 site mutation after inducing differentiation for 8 days. Two-way ANOVA followed by Bonferroni post-tests, n = 3. (E) Relative protein levels of PPARγ and p-PPARγ during differentiation of 3T3L1 cells with N142 site mutation by western blot. PPARγ and p-PPARγ band intensities were normalized relative to the GAPDH bands, and the PPARγ/p-PPARγ ratio was calculated and analyzed. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.005.

Figure 5: The conversion of PPARγ to p-PPARγ was contributed by ERK1/2 phosphorylation when Fstl1 was deficient. (A) The protein levels of p-ERK1/2 and T-ERK1/2 in 3T3L1 cells treated with a p-ERK1/2 inhibitor (U0126) were determined by western blot. (B) Oil Red O staining of the lipid droplets in three groups (Fstl1 knockdown, Fstl1 KD + U0126, control) of 3T3L1 cells after inducing differentiation for 8 days. Oil red O stain was quantified as mentioned above, One-way ANOVA followed by Dunnett’s multiple comparison test. Scale bar, 100 μm. (C) mRNA levels of adipogenic (Fabp4, C/ebpα, Adipoq) and lipogenic genes (Acc, Fas) in 3T3L1 cells as in B. Two-way ANOVA followed by Bonferroni post-tests, n = 3. (D) Western blot analysis of protein levels of p-ERK1/2, T-ERK1/2, p-PPARγ, and PPARγ during differentiation of 3T3L1 cells as in B. p-ERK1/2, T-ERK1/2, p-PPARγ, and PPARγ band intensities were normalized relative to the GAPDH bands. p-ERK/T-ERK and PPARγ/p-PPARγ ratios were analyzed. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.005.
Figure 6: Fstl1 deficiency promoted ERK1/2 phosphorylation and then the conversion of PPARγ to p-PPARγ. (A) Western blot analysis of protein levels of PPARγ, p-PPARγ; p-ERK1/2 and T-ERK1/2 in 3T3L1 cells treated with rosiglitazone at indicated concentrations. (B) Oil red O staining of lipid droplets in 3T3L1 cells of Fstl1 knockdown, Fstl1 KD + RG and control group after inducing differentiation for 8 days. The oil red O stain was extracted and quantitated by measuring absorbance at 492 nm, One-way ANOVA followed by Dunnett’s multiple comparison test. Scale bar, 100 μm. (C) mRNA levels of adipogenic (Fabp4, C/ebpα, Adipoq) and lipogenic genes (Acc, Fas) in cells as mentioned in B. Two-way ANOVA followed by Benferroni post-tests, n = 3. (D) Western blot analysis of protein levels of p-PPARγ, PPARγ, p-ERK1/2, and T-ERK1/2 during differentiation of 3T3L1 cells as in B. p-ERK1/2, T-ERK1/2, p-PPARγ, and PPARγ band intensities were normalized relative to the GAPDH bands, PPARγ/p-PPARγ and p-ERK/T-ERK ratios were analyzed. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.005.

Figure 7: FSTL1 exerted biological effects by inhibiting the integrin β1-mediated activation of the focal adhesion kinase pathway. (A, B) Heatmap of selected differential genes enrichment based on the RNA sequencing of the 3T3L1-NC and 3T3L1-shFstl1 groups after inducing for differentiation. (C) Gene Ontology analysis of differential genes in RNA-seq. (D) Western blot analysis of ITGB1 protein levels in the 3T3L1-NC and 3T3L1-shFstl1 groups after inducing for differentiation. GAPDH was used for loading control, ITGB1 band intensity was normalized relative to the GAPDH band. Student’s t-test, ***P < 0.005. (E, F) The culturing dishes were coated or not coated with Collagen Type I, and the protein levels of p-FAK (s397, s576/577, s925), FAK, p-ERK1/2 and T-ERK1/2 in 3T3L1 cells with Fstl1 knockdown (overexpression in F) and control group were analyzed by western blot. GAPDH was used for the loading control. (G) 293T cells were transfected with plasmids expressing Flag-tagged Fstl1 and HA-tagged Itgb1. Total cell lysate were subjected to IP with Flag or HA antibodies and immunoblotted for FSTL1 and ITGB1. Unspecific IgG antibodies were used as a control. (H) FSTL1 and ITGB1 protein complex was pulled down using glutathione-Sepharose beads and then subjected to western blot analyses with anti-FSTL1 antibody to confirm the presence of FSTL1 (upper). The presence of ITGB1 was detected with anti-ITGB1 antibody (lower). (I) 293T cells were transfected with HA-tagged Itgb1. The culturing dishes were coated or not coated with collagen Type I. ITGB1-HA was immunoprecipitated with HA-agarose and incubated with 100 ng FSTL1 protein. COL1 and ITGB1 were detected with anti-COL1 and anti-HA antibodies, respectively.
p-ERK1/2 was not disrupted (Figure 6D). These results suggest that FSTL1 maintains adipogenesis by inhibiting ERK1/2 phosphorylation and subsequently the PPARγ phosphorylation.

3.5. FSTL1 inhibited ERK1/2 phosphorylation by disturbing the integrin-β1/FAK signaling pathway

As mentioned above, FSTL1 was glycosylated and secreted extracellular to promote adipogenesis. We attempted to determine the membrane receptor-mediated signaling pathway through which FSTL1 activates the intracellular response. We performed a gene expression analysis on 3T3L1-RNA of Fstl1 knockdown and control group after inducing differentiation (Figure s3 and s4). This analysis revealed more than 10 upregulated and 5 downregulated collagen-related genes in the differentiated 3T3L1 cells with Fstl1 knockdown compared with control (Figure 7A). A series of ECM-degradation genes, including matrix metalloproteinase and serine proteinase, were found to decrease in differentiated 3T3L1 cells with Fstl1 knockdown (Figure 7B). Gene ontology enrichment analysis revealed an over-representation of genes associated with integrin-ECM interaction, collagen formation, extracellular matrix organization, and focal adhesion (Figure 7C). However, no integrin-ECM associated pathway was enriched in the undifferentiated 3T3L1 cells with Fstl1 knockdown compared with control (Figure s5). On the basis of RNA-seq study, we hypothesized that FSTL1 might inhibit ERK phosphorylation by attenuating the integrin-β1 mediated signaling during preadipocytes differentiation. Western blot showed that the protein level of ITGB1 was decreased obviously in the Fstl1 knockdown group compared with the control group, while these proteins were decreased obviously in the Fstl1 overexpression group (Figure 7E,F). The relationship among FSTL1, COL1, and ITGB1 then needs to be clarified. To determine whether there is an interaction between FSTL1 and ITGB1, FSTL1 was communoprecipitated with ITGB1 to form a complex by co-IP experiments (Figure 7G). Further, GST-pull down was performed to confirm that FSTL1 directly binds ITGB1 (Figure 7H) but not COL1 (Figure s2G). The binding of FSTL1 to ITGB1 diminished presentation of COL1 to the integrin-β1 receptor (Figure 7I). These data suggest that FSTL1 regulates the downstream FAK/ERK signaling pathway by attenuating the interaction between collagen and integrin-β1.

3.6. FSTL1 was required for HFD-induced obesity development

To evaluate the role of FSTL1 in obesity development, we generated adipocyte specific Fstl1 knockout mice using the aP2-Cre driver strain (Fstl1lox/lox × aP2-cre). Fstl1 gene expression was obviously lower in iWAT of f/f-aP2 mice than in the control group (Figure s6A). But the mRNA and protein levels of FSTL1 in SVF from iWAT were almost equal between the two groups (Figure s6B, C). Fstl1 deletion mice gained similar amounts of body weight and fat mass as the control group with equal amount of food intake under chow diet (CD) feeding (Figure s6D—F). The capability of glucose and insulin tolerance was also equal between the two groups (Figure s6G, H). During the switch from chow diet to high fat diet (HFD), Fstl1 deletion mice gained less amounts of body weight and fat mass (iWAT, eWAT) than control mice (Figure 8A—C). Intraperitoneal glucose tolerance test (iPGTT) showed that the glucose level of Fstl1 deletion mice was lower than that in the...
control group (Figure 8D). Smaller adipocytes were observed in iWAT and eWAT of Fstl1 deletion mice than that of control (Figure 8E,F). Western blot showed that the protein levels of phosphorylated FAK, ERK1/2 and PPARγ were increased in iWAT of Fstl1 deletion mice than control mice (Figure 8G). These data suggest that FSTL1 is necessary for obesity development in vivo.

4. DISCUSSION

Obesity has become a global pandemic, and it is closely associated with other metabolic diseases [33]. Because obesity is characterized by excessive accumulation of white adipose tissue, targeting adipogenesis represents a promising strategy to manage obesity [34]. Serum levels of FSTL1 were found to be higher in overweight and obese subjects than in controls, which indicates a potential pro-obesity effect [35,36]. The specific role and molecular mechanism of FSTL1 in adipogenesis have not been clarified. In this study, we carried out a series of Fstl1 knockdown and overexpression experiments in vitro and verified its function in promoting adipogenesis. In vivo studies, our adipose tissue-specific Fstl1 deletion mice indeed have defects in gaining body weight under HFD feeding. We comprehensively elucidated the role of FSTL1 in adipogenesis both in vitro and in vivo. During differentiation of pre-adipocytes into adipocytes, Fstl1 showed a transient short high-level expression to become subsequently downregulated to background levels at both the mRNA and protein level (Figure 1). We desired a Cre strain that expresses during the adipogenic process in animal studies. Adiponectin-cre lines are the best Cre strains used for targeting mature adipocytes, while the Pdgfra-Cre lines are preferable for targeting adipocyte progenitors in vivo. Ap2-Cre mediated recombination occurs not only in mature adipocytes, but also in adipocyte progenitors [37]. We chose Ap2-Cre in our animal model, although it was studied to be expressed not only in adipose tissue but some other cell types. However, we found that FSTL1 was not efficiently deleted in adipocyte precursor cells of KO mice. The deficiency of FSTL1 in the KO mice was to inhibit the size of adipocytes (hypertrophy) rather than the number (hyperplasia) of precursor cells. Compared to the control group, the KO mice show an improved metabolic profile in vivo, which can be helped with cell culture studies. L.S. helped with RNA-seq and data analysis.

Peroxisome proliferator-activated receptor γ (PPARγ) is a key regulatory factor for adipogenesis and obesity [9]. Phosphorylated modification was proved to inhibit the activity of PPARγ, and thus the process of adipogenesis. PPARγ phosphorylation was found to increase in the obese state [13]. Treatment of mice with classical and non-classical thiazolidinediones (TZDs), such as rosiglitazone, prevents PPARγ phosphorylation and inducing expression of a constituent lipid gene [38]. The efficacy of synthetic ligands of PPARγ in controlling blood glucose has been widely recognized. However, their clinical usage is limited due to side effects, including weight gain, fluid retention, bone fracture, cardiovascular disease, and bladder cancer [39]. Many recent studies have focused on the post-translational modifications of PPARγ, such as phosphorylation, acetylation, ubiquitination et al. In our study, we find that FSTL1 inhibits the conversion of PPARγ to p-PPARγ, which provides a potential therapeutic target in combating obesity. FSTL1 was involved in multiple signaling pathways; binding to membrane receptors has been shown, but other molecular partners probably exist [40—43]. In our study, we found that FSTL1 inhibited PPARγ phosphorylation to promote adipogenesis. It was reported that the phosphorylation of PPARγ could be modified by CDK5, p-ERK1/2 and other cytokines [26,32]. We proved that FSTL1 inhibited the conversion of PPARγ to p-PPARγ by reducing ERK1/2 phosphorylation. We were then curious about the signaling pathway through which FSTL1 regulates ERK1/2 phosphorylation. Our gene expression analysis showed that the organization of extracellular matrix (collagen, tenascin, MMP et al.) was disrupted when FSTL1 was lost, and the signaling pathways associated with ECM-receptor interaction were enriched. It was reported that the downstream signaling of integrin-β1 such as FAK and ERK is involved in adipocyte differentiation [44]. We finally concluded that the role of FSTL1 in the late stage of adipogenic differentiation was related with FAK/ERK signaling pathway; however, its role in the phase of mitotic clonal expansion prior to differentiation and the phase of determination was possibly otherwise related. Here, our study demonstrates the conversion between PPARγ and p-PPARγ as a potential downstream target of FSTL1, and we propose a new mechanism of FSTL1 as a component of extracellular matrix. We have proven that FSTL1 directly binds with ITGB1, but how FSTL1 inhibits the binding between collagen and integrin-β1 is still unclear in this research. Previous reports have shown that integrin-β1 regulates various biological functions, including cell migration and signal transduction, particularly in the context of cancer [45—47]. It will also be interesting to determine whether morphofunctional modifications of adipocytes are involved in the activation of FSTL1 in promoting adipogenesis. Together, our studies reveal that FSTL1 is an important adipokine in promoting adipogenesis and obesity development. N-glycosylation is necessary for the function of FSTL1 in adipogenesis, and modification at Asp142 is of great significance. FSTL1 promotes adipogenesis by disrupting the interaction between collagen and integrin-β1, which caused the inhibitory effect of FAK and ERK1/2 phosphorylation, and then the PPARγ phosphorylation. Thus, PPARγ phosphorylation regulated by FSTL1 might prove to be a novel target in adipogenesis and obesity.

AUTHOR CONTRIBUTIONS

Y.G. and D.L.F. conceived the project and designed research. D.L.F. and Y.X.S performed the experiments. X.W.J., Ch.Y., and T.L. provided help in tissue processing and assistance. L.W.W., L.L., and B.P.D. helped with cell culture studies. L.S. helped with RNA-seq and data analysis. D.L.F. and Y.G. analyzed the data and wrote the original draft.
ACKNOWLEDGMENTS

We thank Dr. H.B.R. from University of Minnesota for providing counseling on this study and final editing of the manuscript. The present study was supported by the Beijing Natural Science Foundation of China (grant no. 5214022; 5202004).

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2021.101400.

REFERENCES

[1] Blüher, M., 2019. Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology 15(9):288–298. https://doi.org/10.1038/s41574-019-0176-8.
[2] Cinti, S., 2018. Adipose organ development and remodeling. Comprehensive Physiology 8(4):1357. https://doi.org/10.1002/cphy.c170042.
[3] Petrus, P., Meijerdt, N., Corrales, P., Lecoubre, S., Li, Q., Maldonado, E., et al., 2018. Transforming growth factor-β3 regulates adipocyte number in subcutaneous white adipose tissue. Cell Reports 25(3):551–560. https://doi.org/10.1016/j.celrep.2018.09.065.
[4] Hepler, C., Gupta, R.K., 2017. The expanding problem of adipose depot remodeling and postnatal adipocyte progenitor recruitment. Molecular and Cellular Endocrinology 445:95–108. https://doi.org/10.1016/j.mce.2016.10.011.
[5] Sanchez-Gurmaches, J., Guerín, D.A., 2014. Adipocytes arise from multiple lineages that are heterogeneously and dynamically distributed. Nature Communications 5(1). https://doi.org/10.1038/ncomms5099.
[6] Modica, S., Straub, L.G., Balaz, M., Sun, W., Varga, L., Stefanicka, P., et al., 2016. Bmp4 promotes a Brown to white-like adipocyte shift. Cell Reports 16(9):2243–2258. https://doi.org/10.1016/j.celrep.2016.07.048.
[7] Chen, N., Wang, J., 2018. Wnt/Catenin signaling and obesity. Frontiers in Physiology 9. https://doi.org/10.3389/fphys.2018.00792.
[8] Sanchez-Gurmaches, J., Guertin, D.A., 2014. Adipocytes arise from multiple lineages that are heterogeneously and dynamically distributed. Nature Communications 5(1). https://doi.org/10.1038/ncomms5099.
[9] Hepler, C., Gupta, R.K., 2017. The expanding problem of adipose depot remodeling and postnatal adipocyte progenitor recruitment. Molecular and Cellular Endocrinology 445:95–108. https://doi.org/10.1016/j.mce.2016.10.011.
[10] Wagner, R., Hronimous, A., Lamprinou, A., Heni, M., Hatzigiakelis, E., Ullrich, S., et al., 2014. Peroxisome proliferator-activated receptor gamma (PPARγ) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans. Molecular Metabolism 3(6):676–680. https://doi.org/10.1016/j.molmet.2014.07.001.
[11] Mayoral, R., Osborn, O., McNeils, J., Johnson, A.M., Oh, D.Y., Iziqierdo, C.L., et al., 2015. Adipocyte SIRT1 knockout promotes PPARY activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Molecular Metabolism 4(5):378–391. https://doi.org/10.1016/j.molmet.2015.02.007.
[12] Lascar, D., Rosenwald, M., Kiehlmann, E., Balaz, M., Tall, B., Opitz, L., et al., 2018. Peroxisome proliferator activated receptor gamma controls mature Brown adipocyte inducibility through glycerol kinase. Cell Reports 22(3):760–773. https://doi.org/10.1016/j.celrep.2017.12.067.
[13] Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Boström, P., Laznik, D., et al., 2010. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARY by Cdk5. Nature 466(7305):451–456. https://doi.org/10.1038/nature09291.
[14] Paula Mota De Sa, A.J.R.H., 2017. Transcriptional regulation of adipogenesis. Comprehensive Physiology 7:635–674. https://doi.org/10.1002/cphy.c160022.
[15] Geng, Y., Dong, Y., Yu, M., Zhang, L., Yan, X., Sun, J., et al., 2011. Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proceedings of the National Academy of Sciences 108(17):7058–7063. https://doi.org/10.1073/pnas.1007293108.
[16] Liu, X., Liu, Y., Li, X., Zhao, J., Geng, Y., Ning, W., 2017. Follistatin-like 1 (Fstl1) is required for the normal formation of lung airway and vascular smooth muscle at birth. PLoS One 12(6):e0177899. https://doi.org/10.1371/journal.pone.0177899.
[17] Hambrock, H.O., Kaufmann, B., Müller, S., Hanisch, F., Nose, K., Paulsson, M., et al., 2004. Structural characterization of TSC-36/flik. Journal of Biological Chemistry 279(12):11727–11735. https://doi.org/10.1074/jbc.m309318200.
[18] Liu, D., Wang, Y., Xu, N., Wei, Q., Wu, M., Li, X., et al., 2011. Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Research & Therapy 13(1):R17. https://doi.org/10.1186/ar3241.
[19] Wang, Y., Li, D., Xu, N., Tao, W., Zhu, R., Sun, R., et al., 2011. Follistatin-like protein 1: a serum biochemical marker reflecting the severity of joint damage in patients with osteoarthritis. Arthritis Research & Therapy 13(6):R193. https://doi.org/10.1186/ar3522.
[20] Raschke, S., Eckel, J., 2013. Adipo-Myxokines: two sides of the same coin—mediators of inflammation and mediators of exercise. Mediators of Inflammation 2013:1–16. https://doi.org/10.1155/2013/202724.
[21] Rodríguez, A., Becerril, S., Ezquerra, S., Méndez-Giménez, L., Frühbeck, G., 2017. Crosstalk between adipokines and myokines in fat browning. Acta Physiologica 219(2):362–381. https://doi.org/10.1111/apha.12686.
[22] Wu, Y., Zhou, S., Smas, C.M., 2010. Downregulated expression of the secreted glycoprotein follistatin-like 1 (Fstl1) is a robust hallmark of prediabetic to adipocyte conversion. Mechanisms of Development 127(3–4):183–202. https://doi.org/10.1016/j.mod.2009.12.003.
[23] Wei, K., Serpooshan, V., Hurtado, C., Diez-Cuñado, M., Zhao, M., Maruyama, S., et al., 2015. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 525(7570):479–485. https://doi.org/10.1038/nature15372.
[24] Magadum, A., Singh, N., Kurian, A.A., shockar, M.T.K., Chepurko, E., Zangi, L., et al., 2010. The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and regulates the severity of joint damage in patients with osteoarthritis. Arthritis Research & Therapy 13(6):R193. https://doi.org/10.1186/ar3522.
[25] Howe, E.N., Burnett, M.D., Justice, M.E., Schnepp, P.M., Hedrick, V., Clancy, J.W., et al., 2020. Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth. Nature Communications 11(1). https://doi.org/10.1038/s41467-020-16832-2.
[26] Fuentes, P., Aucúñ, M.J., Cifuentes, M., Rojas, C.V., 2010. The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and regulates the severity of joint damage in patients with osteoarthritis. Arthritis Research & Therapy 13(6):R193. https://doi.org/10.1186/ar3522.
[27] Ruiz-Ojeda, F.J., Wang, J., Bäcker, T., Krueger, M., Zamani, S., Rosowski, S., et al., 2021. Active integrins regulate white adipose tissue insulin sensitivity and brown fat thermogenesis. Molecular Metabolism 45:101147. https://doi.org/10.1016/j.molmet.2020.101147.
[28] Dong, Y., Geng, Y., Li, L., Li, X., Yan, X., Fang, Y., et al., 2015. Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice. Journal of Experimental Medicine 212(2):235–252. https://doi.org/10.1084/jem.20121878.
Fang, D., Shi, X., Lu, T., Ruan, H., Gao, Y., 2019. The glycoprotein follistatin-like 1 promotes brown adipose thermogenesis. Metabolism 98:16–26. https://doi.org/10.1016/j.metabol.2019.05.008.

Peirce, V., Carobbio, S., Vidal-Puig, A., 2014. The different shades of fat. Nature 510(7503):76–83. https://doi.org/10.1038/nature13477.

Rosen, E.D., MacDougald, O.A., 2006. Adipocyte differentiation from the inside out. Nature Reviews Molecular Cell Biology 7(12):885–896. https://doi.org/10.1038/nrm2066.

Banks, A.S., McAllister, F.E., Camporez, J.P.G., Zushin, P.H., Jurczak, M.J., Laznik-Bogoslavski, D., et al., 2015. An ERK/Cdk5 axis controls the diabeticogenic actions of PPARγ. Nature 517(7534):391–395 https://doi.org/10.1038/nature13887.

Sung, H., Siegel, R.L., Miller, K.D., Jemal, A., 2019. Cancer statistics, 2019. CA. A Cancer Journal for Clinicians 69(1):7–34. https://doi.org/10.3322/caac.21551.

Ahmadian, M., Suh, J.M., Hahn, N., Liddle, C., Atkins, A.R., Downes, M., et al., 2013. PPARγ signaling and metabolism: the good, the bad and the future. Nature Medicine 19(5):557–566. https://doi.org/10.1038/nm.3159.

Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R., et al., 2017. Heart disease and stroke statistics—2017 update: a report from the American heart association. Circulation 135(10). https://doi.org/10.1161/CIR.0000000000004465.

Maruyama, S., Nakamura, K., Papanicolaou, K.N., Sano, S., Shimizu, I., Asaumi, Y., et al., 2016. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Molecular Medicine 8(8):949–966. https://doi.org/10.15252/emmm.201506151.

Siegel, R.L., Miller, K.D., Jemal, A., 2019. Cancer statistics, 2019. CA. A Cancer Journal for Clinicians 69(1):7–34. https://doi.org/10.3322/caac.21551.

Sundaram, G.M., Ismail, H.M., Bashir, M., Muhuri, M., Vaz, C., Nama, S., et al., 2017. EGF hijacks miR-198/FSTL1 wound-healing switch and steers a two-pronged pathway toward metastasis. Journal of Experimental Medicine 214(10):2889–2900. https://doi.org/10.1084/jem.20170354.

Kaburagi, T., Kizuka, Y., Kitazume, S., Taniguchi, N., 2017. The inhibitory role of α2,6-sialylation in adipogenesis. Journal of Biological Chemistry 292(6):2278–2286. https://doi.org/10.1074/jbc.M116.747667.

Sulzmaier, F.J., Jean, C., Schlaepfer, D.D., 2014. FAK in cancer: mechanistic findings and clinical applications. Nature Reviews Cancer 14(9):598–610. https://doi.org/10.1038/nrc3792.

Cooper, J., Giancotti, F.G., 2019. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell 35(3):347–367. https://doi.org/10.1016/j.ccell.2019.01.007.

Zhou, J., Yi, Q., Tang, L., 2019. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review. Journal of Experimental & Clinical Cancer Research 38(1). https://doi.org/10.1186/s13046-019-1265-1.